Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Novo-Nordisk-Wegovy

More Like This

PR Newswire associated0

Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025

PR Newswire associated0

Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting

MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults

PR Newswire associated0

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

PR Newswire associated0

Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication